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Abstract
Atopic dermatitis (AD) is a widely spread cutaneous chronic disease characterised by sensitive reactions (eg. eczema) to
normally innocuous elements. Although relatively little is understood about its underlying mechanisms due to its
complexity, skin barrier dysfunction has been recognised as a key factor in the development of AD. Skin barrier homeostasis
requires tight control of the activity of proteases, called kallikreins (KLKs), whose activity is regulated by a complex network
of protein interactions that remains poorly understood despite its pathological importance. Characteristic symptoms of AD
include the outbreak of inflammation triggered by external (eg. mechanical and chemical) stimulus and the persistence and
aggravation of inflammation even if the initial stimulus disappears. These characteristic symptoms, together with some
experimental data, suggest the presence of positive feedback regulation for KLK activity by inflammatory signals. We
developed simple mathematical models for the KLK activation system to study the effects of feedback loops and carried out
bifurcation analysis to investigate the model behaviours corresponding to inflammation caused by external stimulus. The
model analysis confirmed that the hypothesised core model mechanisms capture the essence of inflammation outbreak by
a defective skin barrier. Our models predicted the outbreaks of inflammation at weaker stimulus and its longer persistence
in AD patients compared to healthy control. We also proposed a novel quantitative indicator for inflammation level by
applying principal component analysis to microarray data. The model analysis reproduced qualitative AD characteristics
revealed by this indicator. Our results strongly implicate the presence and importance of feedback mechanisms in KLK
activity regulation. We further proposed future experiments that may provide informative data to enhance the system-level
understanding on the regulatory mechanisms of skin barrier in AD and healthy individuals.
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Introduction
Atopic dermatitis (AD) is a common chronic allergic skin disease
characterised by dry, scaly skin, inflammation, increased skin
permeability, susceptibility to allergy causing sensitive reactions to
normally innocuous elements and vulnerability to surface infection
[1,2]. The lifetime prevalence of AD is estimated to 15–30% in
children and 2–10% in adults while the incidence of AD has
increased by 2- to 3-fold during the past 3 decades in industrialised
countries [1], and thus AD has significant socioeconomic and
personal impacts in these countries [3]. Recently, skin barrier
dysfunction has been recognised as one of the key factors in the
development of AD [2,4,5], although relatively little is understood
about its underlying mechanisms due to its complexity.
The skin barrier is physically composed of the cornified layer,
where keratin-filled and anucleated keratinocytes (corneocytes) are
densely packed with skin lipids (Fig. 1A). Skin barrier homeostasis is
attained by balancing the differentiation of granular layer keratino-
cytes to corneocytes against elimination of corneocytes at the skin
surface (desquamation) [6]. The latter occurs as the result of cleavage
of corneodesmosomes (Fig. 1B), which bind corneocytes together, by
serine proteases called kallikreins (KLKs) [7]. Excessive activities of
KLKs can impair the skin barrier via premature breakdown of
corneodesmosomes by KLKs [8] and increase corneocyte desqua-
mation. Accumulating evidence indicates malfunctions in the spatial
and temporal control of KLK activity in AD patients is one of the
main causes for their defective skin barrier homeostasis [9].
KLKs are synthesised as inactive precursors and are secreted
into the extracellular space, where they are activated by another
active KLK by irreversible proteolysis (Fig. 1B) [10]. The activity
of each KLK is further regulated by direct interaction with
proteinase inhibitors such as Lympho-epithelial Kazal-type related
inhibitor (LEKTI) [11], and by changes in pH [12]. Indeed,
compared to healthy control (HC), AD patients have the following
three characteristics: (1) higher protein level of KLKs in stratum
corneum [13], (2) significant decrease in the expression of SPINK5
encoding LEKTI [14], and (3) higher pH level [15,16], all of
which result in higher KLK activity. In addition to KLKs and
LEKTI, recent findings have suggested that protease-activated
receptors type 2 (PAR2) plays a significant role in skin barrier
homeostasis [17–19]. PAR2 is cleaved and activated by active
KLKs, resulting in Ca2z release and mitogen activated protein
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status), PAR2 signalling is reported to regulate the differentiation
of keratinocytes [20], while in pathological conditions including
AD, this signalling upregulates cytokine production by keratino-
cytes and induces immune response [21].
The activities of KLKs and PAR2s are thus tightly regulated by a
complex network of protein-protein interactions that remain, despite its
pathological importance, poorly understood. Therefore, it is indis-
pensable to reveal how different components such as KLK, LEKTI,
PAR2 and pH affect the systems behaviour by their mutual
interactions and feedback regulation, and to understand how these
mechanisms are dysregulated at the system-level in AD patients.
However, experimental data are currently limited and the entire
regulatory mechanism is still obscure.
AD is a notoriously chronic disease: sensitive reactions including
inflammation occur easily by external stimulus (eg. scratching) and may
persist or even aggravate, even if the initiating stimulus no longer exists.
These features, notably outbreak, persistence, and aggravation of
inflammation, suggest the presence of a positive feedback loop [22,23]
in the regulatory system for KLK activity. Although such feedback
loops have not been explicitly identified to date, feedback regulatory
mechanisms of KLK activity are further suggested by the following
experimental evidence: (1) cells within the inflammatory infiltrate
produce KLKs as a product of the inflammatory response, in
proportional level with the severity of a flare of AD [7], (2) both KLKs
[13] and PAR2 [24] proteins are increased in AD lesions, (3) patients
with different deficiency in SPINK5 gene show different KLK
expression level [25], (4) the kinetics of skin barrier recovery is
accelerated in PAR2 knockout than wild-type [26], (5) keratinocytes
have receptors for inflammatory cytokines such as IL1 and IL8
(downstream signals of PAR2 activation), thus can be activated in an
autocrine manner [27,28]. Importantly, KLK, LEKTI and PAR2 do
not interact inside the cell, but are transported outside of the cell
separately and only interact at the cell surface and in the extracellular
space [9].
Accordingly, we conduct a systems-level investigation of the
feedback regulation of KLK activity in skin. To achieve the overall
aim of better understanding underlying mechanisms of skin barrier
dysfunction in AD patients, we carry out the investigation in three
steps. First, we develop a novel mathematical model of the KLK
activation system and provide a framework to coherently explain
the current experimental knowledge on AD. The mathematical
model we propose in this paper consists of four core mechanisms
for KLK activation: (1) KLK self-activation, (2) KLK inhibition by
LEKTI, (3) PAR2 activation by KLK, and (4) feedback regulation
of KLK and LEKTI via activated PAR2. The first three
mechanisms have been rather well characterised experimentally
while the feedback mechanism has been implicitly suggested based
on different experimental evidence as described above [7,13,24–26]
and awaits the explicit identification by experiments. Second, using
this mathematical framework, we investigate the fundamental and
core mechanisms responsible for qualitatively different behaviours
of the system to characterise HC and AD patients. We hypothesise
models with different feedback loops and identify the plausible
system behaviours by bifurcation analysis. The proposed models
successfully reproduce the clinically well-known and essential AD
features: persistent inflammation triggered by lower level of external
stimulus for AD than for HC. To gain further insight, we perform
sensitivity analysis [29], motivating the detailed study of parameter-
dependencies of system behaviours; furthermore, this analysis
identifies the important balance between degradation rates and
rates for feedback kinetics. Lastly, the model predictions are verified
with experimental data. Since PAR2 activity is difficult to directly
measure by conventional experiments including Western blotting of
signalling proteins, we propose a novel way of evaluating PAR2
downstream signal activities using microarray analysis. Specifically,
we apply principal component analysis (PCA) to microarray data of
HC and AD samples and derive an indicator (PAR2 score) of the
PAR2 downstream inflammation level that can capture the
difference between HC and AD patients. The model predictions
Figure 1. Models of skin desquamation. A: Cartoon model of skin desquamation. Skin barrier is physically composed of the cornified layer,
where keratin-filled and anucleated keratinocytes (corneocytes) are densely packed with skin lipids. Corneocytes are interconnected by
corneodesmosomes. Skin desquamation occurs by elimination of corneocytes at the skin surface. B: Cartoon model of protein interactions involved in
KLK5 activation regulation. (a) KLK5 and their inhibitor LEKTI are secreted from granular cells into the intercellular space at the interface of cornified
and granular layers; (b) KLK5 self-activates by proteolysis; (c) Direct binding of LEKTI inhibits the activity of KLK5; (d) Active KLK5 physically cleaves
corneodesmosomes, which bind corneocytes together, resulting in elimination of corneocytes; (e) PAR2 is cleaved by active KLK5 to be activated and
internalized. Figure was modified from [9]. C: Simplified model for KLK5 activation regulation system proposed in this paper. KLK5* and PAR2*
represent the activated forms of KLK5 and PAR2, respectively. (a) KLK5 self-activation by proteolysis; (b) Association and dissociation of LEKTI and
KLK5*; (c) PAR2 activation by KLK5*; (d) Feedback from PAR2* to production of LEKTI (FL); (e) Feedback from PAR2* to production of KLK5 (FK);
Inflammation level is denoted by the level of PAR2*.
doi:10.1371/journal.pone.0019895.g001
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confirm the coherency of the model. All the results presented here
support the presence and significance of feedback loops in the
regulation of KLK activity, and thus this work attempts to motivate
a variety of future experiments for further study in order to better
understand the fundamental regulatory mechanisms of skin barrier
homeostasis in AD and healthy individuals.
Results
Construction of mathematical models: Model overview
We developed an ordinary differential equation model for
regulation of KLK activation at the interface of cornified and
granular layers in skin (Fig. 1C) consisting of three main mechanisms
(dotted lines in Fig. 1C): (1) KLK self-activation, (2) KLK inhibition by
LEKTI, and (3) PAR2 activation by active KLK, and hypothesised
feedback loops (dotted arrows in Fig. 1C) from activated PAR2 to
KLK and LEKTI production. This model focuses on KLK5, which is
the primary KLK for skin desquamation and is involved in all four of
the aforementioned mechanisms [30]. The complete model descrip-
tion is shown in the Methods section, together with the nominal
parameter values in Table 1.
In the first mechanism, KLK5 self-activation (Fig. 1C(a)), an
inactive precursor form of KLK5 is cleaved to be an activated
KLK5 (denoted by KLK5* hereafter) by itself. In the second
mechanism, KLK5 inhibition (Fig. 1C(b)), LEKTI binds to and
almost perfectly inactivates KLK5* [11] by producing the
complex LEKTI-KLK5* that has no cleaving activity. In the
next mechanism, PAR2 activation by KLK5* (Fig. 1C(c)), inactive
PAR2 is cleaved and activated by KLK5*. For the non-
inflammatory states, a small amount of active PAR2 (denoted S)
is constitutively produced, maintaining the basal activity of KLK5
production for the normal desquamation process (Fig. 2). Various
external stimuli can influence S to be fluctuated around its
nominal value. The integrated strength of external stimuli is
accordingly represented by S. For the inflammatory states, a large
amount of activated PAR2 (denoted by PAR2* hereafter) is
induced and internalized, which then transduces stronger
canonical signalling cascades and increases the expression of
inflammatory genes including IL1a, IL1b, IL8 and TNF-a. The
inflammation level is accordingly represented by the level of
PAR2* in our model.
Positive feedback loops from PAR2* to KLK5 production
would reflect that KLK concentration increases when PAR2 is
activated and inflammation occurs [7]. We investigated the
possibilities of both positive (Model 1) and negative (Model 2)
feedbacks from PAR2* to LEKTI production, as there is no strong
experimental evidence to discriminate the most plausible feedback
mechanism. The strength of the feedback from PAR2* to KLK5
and LEKTI are denoted by fK and fL in our model, respectively.
We assumed that PAR2 production is constant [31].
Model behaviours: Outbreak and persistence of
inflammation
We first confirmed that the proposed model exhibits the
expected characteristic behaviours of AD, that is, the flare of
inflammation by external stimulus and its persistence despite a
decrease of initial external stimulus (eg. scratching). We used
bifurcation diagrams to delineate qualitatively different behav-
iour; they characterise the type of model behaviours in the
presence of an external stimulus, similar to dose response curves
in experimental biology which can be used to identify such
changes in behaviour. As the external stimulus increases, the
non-inflammatory (zero) state may change whereby there are
two stable (bistable) steady states, corresponding to a high
inflammatory and a non-inflammatory state. Bifurcation
diagrams for Model 1 (Fig. 3A) illustrate stable and unstable
steady states corresponding to solid and dotted lines, respec-
tively. The thickness of each bifurcation curve corresponds to
the strength, fK, of the positive feedback to KLK5. Stronger
positive feedback leads to more persistent inflammation, as
shown by the larger range of the bistability. Persistent
inflammation means that a significant decrease of external
stimulus is required for the inflammation to cease. The
inflammation level is also higher for the system with stronger
feedback. The similar bifurcation behaviours are observed for
Model 2 with negative feedback from PAR2* to LEKTI
(supporting Fig. S1). The parameter dependency, especially to
the feedback strength, of the bifurcations is investigated
throughout this work.
The observed behaviours (Fig. 3A) are summarised in Fig. 4B:
there is no inflammation (inflammation level is zero) at low
external stimulus level S;a sS increases, inflammation outbreaks at
a certain stimulus threshold for inflammation outbreak, Sz, where
there is a jump from no inflammation state to a higher
inflammation state. Once inflammation occurs, the inflammation
Table 1. Definitions of system parameters and values used in
simulations.
Parameter Description Nominal value
ka LEKTI-KLK5* association rate 1 (pH 4.5) [12]
3 (pH 6.5) [12]
kd LEKTI-KLK5* dissociation rate 1 (pH 4.5) [12]
2.5|10{3 (pH 6.5)
[12]
k KLK5 activation rate 10 (pH 4.5) [50]
50 (pH 6.5) [50]
kP PAR2 activation rate &k [50]
dL LEKTI degradation rate 0.5
dK KLK5 degradation rate 1
dLK LEKTI-KLK5* degradation rate &dK
dK  KLK5* degradation rate &dK
dP PAR2 degradation rate 0.5
dP  PAR2* degradation rate &dP
tL LEKTI production capability 1 (HC) [14]
0.5 (AD-LEKTI) [14]
CK Half-saturation of KLK5 activation 50
CP Half-saturation of PAR2 activation &CK
CL Inhibition constant for Model 2 5
mP Basal production rate for PAR2 10
mL Basal production rate for LEKTI 1
mK Basal production rate for KLK5 0
fKS Rate of KLK5 production by stimulus 0.5
fLS Rate of LEKTI production by stimulus 0.05 (Model 1)
0 (Model 2)
fK Feedback strength from PAR2* to KLK5 0–1
fL Feedback strength from PAR2* to LEKTI 0–0.5 (Model 1)
0–10 (Model 2)
doi:10.1371/journal.pone.0019895.t001
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deactivation threshold of stimulus, S{, which is much smaller
than the inflammation threshold Sz. The hysteresis curve
represents the persistence of inflammation despite the decrease
of the external stimulus. At S~S{, the inflammation level finally
returns to zero, that is, the inflammation stops.
AD characteristics: Smaller inflammation threshold for AD
than for HC
We then verified that the proposed model captures character-
istics of AD patients compared to HC. We characterised AD
patients by the following two conditions: (1) limited LEKTI
production rate and (2) high pH, based on the observation that
LEKTI expression in AD is about 50% of that of HC [14] and AD
skin generally exhibits higher pH (around 6.5) compared to HC
(pH around 4.5), although there are large variances of the pH level
for each individual and for different skin areas [15]. We compared
the behaviours for the following three conditions: (1) limited
LEKTI production rate at pH 4.5 (AD-LEKTI), (2) full LEKTI
production rate at pH 6.5 (AD-pH), and (3) full LEKTI
production rate at pH 4.5 (HC). AD-LEKTI condition is
investigated by setting tL, a parameter representing the LEKTI
production rate in our model, to be half of the full LEKTI
production rate. AD-pH condition is studied by changing pH-
dependent parameters, k,kP,ka, and kd according to the literature
(see Methods). We investigated AD-LEKTI and AD-pH condi-
tions to clarify the respective effects of limited LEKTI production
rate and high pH separately.
The bifurcation diagrams of Model 1 at different conditions
clearly exhibit a lower inflammation threshold for both AD-
LEKTI (blue) and AD-pH (red) conditions than that for HC
(black), and a much higher inflammation level for AD-pH
condition (Fig. 3B). This is consistent with the clinical features of
AD which shows more sensitivity to external stimulus: low levels of
external stimulus, which are innocuous to HC, can trigger
inflammation in AD patients. Qualitatively similar behaviour
was observed for Model 2 (Fig. S2). The lower inflammation
threshold in AD conditions compared to HC is similarly observed
Figure 2. PAR2 signalling downstreams in granular cells. A: For the non-inflammatory states, a small amount of active PAR2, S,i s
constitutively produced, maintaining the basal activity of KLK5 production for the normal desquamation process. Various external stimuli can
influence S to be fluctuated around its nominal value. B: For the inflammatory states, a large amount of activated PAR2, [PAR2*], is induced and
internalized, which then transduce stronger canonical signalling cascades and increase the expression of inflammatory genes including IL1a, IL1b, IL8
and TNF-a.
doi:10.1371/journal.pone.0019895.g002
Figure 3. Bifurcation diagrams of Model 1 showing the inflammation outbreak and its persistence. Inflammation outbreak and its
persistence appear as bistability of inflammation level as the external stimulus level changes. The solid and dotted lines show the stable and unstable
steady states, respectively. A: The thickness of each bifurcation curve corresponds to positive feedback strength (fK~0:4,0:6,0:8;fL~0:2). Stronger
positive feedback leads to more persistent inflammation, as is shown by the larger range of the bistability. B: The behaviours are compared for HC
(black), AD-LEKTI (blue), and AD-pH (red) with fK~0:4 and fL~0:2. The inflammation threshold is lower for AD conditions than that for HC.
doi:10.1371/journal.pone.0019895.g003
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more detailed and quantitative comparison of behaviours for
varied conditions with different feedback strength is shown in the
next section.
Classification of observed bifurcations
The bifurcation diagrams shown above exhibited bistability,
indicating inflammation outbreaks by external stimuli; however,
the proposed models can exhibit other behaviours for certain
systems parameter combinations. Figure 4A demonstrates the four
typical behaviours:
N Reversible bistability (red): Bistable states appear for
S{vSvSz with the deactivation threshold S{ in the
biologically feasible region of Sw0. The inflammation is
reversible, that is, it outbreaks at Sz and ceases at S{;
N Irreversible bistability (blue): Bistable states appear for SvSz.
The inflammation is irreversible, that is, it persists even if S
decreases to zero once it outbreaks at the threshold Sz,a s
S{v0 is not in the biologically feasible region of Sw0.
N Continuous monostability (green): Monostable state appears
for all S. In this case, the inflammation occurs gradually as S
increases, which is contradictory to on/off switching of
inflammation observed in AD symptoms;
N Discontinuous monostability (cyan): Monostable state appears
for low and high S and there is some range of S for which no
stable points exist.
Among these four behaviours, only the reversible and
irreversible bistability match the characteristic on/off switching
of inflammation, while continuous and discontinuous monostabil-
ity behaviours are not biologically plausible. Strictly speaking, S
may not be decreased below a certain level in reality, and thus the
reversibility of this model may not correspond to spontaneous
regression of lesion in clinical circumstances. Therefore, the
difference between reversible and irreversible bistability should be
interpreted as an ordered scale for the disease severity: irreversible
bistability corresponds to a more severe case. The systems that
exhibit irreversible bistability and the ones of reversible bistability
with small S{ have to be modulated by changing some systems
parameters to increase the deactivation threshold into the
biologically feasible region, for example by topical cortiocosteroid,
in order to stop the inflammation.
Effects of feedback strength on model behaviours
The four distinct bifurcation behaviours (Fig. 4A) are exhibited
by Model 1 by varying feedback strength for different conditions
(Fig. 5). We varied the feedback strength about 1000-fold and
identified the range that exhibits the change of bifurcation patterns
of our interest. Top rows in Fig. 5A show the patterns we observed
for different pairs of fK and fL, with the colours corresponding to
those in Fig. 4A for different behaviours: reversible bistability (red),
irreversible bistability (blue), continuous monostability (green), and
discontinuous monostability (cyan). The patterns gradually change
from discontinuous and continuous monostability at the top left
corner to reversible bistability and then irreversible bistability at
the lower right corner, where the KLK production rate is higher
due to larger feedback strength to KLK (fK) and the LEKTI
production rate is lower due to smaller feedback to LEKTI (fL).
Stronger KLK activation thus results in more severe symptoms of
irreversible bistability. The irreversible bistability behaviour is
observed in larger parameter domains of the lower right corner for
AD conditions. This result confirms that our model captures an
aspect of the difference between HC and AD: the pair (fK,fL) that
results in the reversible bistability in HC leads to the irreversible
bistability in AD conditions. That is, AD systems exhibit more
severe symptoms than HC.
Bistable behaviours observed for varied feedback strengths and
different conditions were investigated in more detail by calculating
two quantitative indices (Fig. 4B) for bistable behaviours: (1) the
inflammation threshold Sz and (2) the range of bistability,
r~Sz{S{, which indicates the necessary decrease of the
external stimulus level for the inflammation to cease. Smaller
values of Sz indicate an increased sensitivity of the skin to external
stimulus; larger values of r indicate that the inflammation is more
persistent. Note, however, that r is only calculated for reversible
bistability, not irreversible, as S{ does not appear in the
biologically feasible region for irreversible bistability.
Model 1 predicts much smaller Sz for AD conditions (middle
rows in Fig. 5A) and large r for stronger KLK activation at the
Figure 4. (A) Four bifurcation patterns exhibited by our models and (B) quantitative indices of bistable behaviours. A: Reversible
bistability (red), irreversible bistability (blue), continuous monostability (green), and discontinuous monostability (cyan). Bistability patterns match the
characteristic switching of inflammation. Irreversible bistability patterns correspond to more severe symptoms than reversible bistability patterns. B:
Inflammation outbreaks at the inflammation threshold S~Sz and persists until S decreases to reach the deactivation threshold S{, where the
inflammation level returns to zero. The range of bistability r~Sz{S{ represents the required level of decrease in the external stimulus for the
inflammation to cease. Smaller values of Sz indicate an increased sensitivity of the skin to external stimulus; Larger values of r indicate that the
inflammation is persistent.
doi:10.1371/journal.pone.0019895.g004
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Fig. 5A), as is consistent with the fact that the inflammation is
more persistent with stronger KLK activation. Moreover, the
stimulus has to decrease to almost zero for the inflammation to
stop when KLK activation is strong, as shown by r being almost
equal to Sz. If KLK activation becomes stronger, the system
exhibits irreversible bistability.
The result of the same investigation for Model 2 (Fig. S3)
exhibits similar qualitative features as those observed for Model 1.
Note that KLK activation is stronger at the top right corner due to
larger fK (resulting in more KLK production) and larger fL
(resulting in less LEKTI production) in this model. Model 2 clearly
demonstrates the transition of the bifurcation pattern from
reversible to irreversible bistability as fK increases (Fig. S3A).
The fL-independence of the pattern is consistent with the result of
the sensitivity analysis demonstrated in the next section (Fig. 6).
Model 2 exhibits smaller Sz for AD conditions than for HC,
similarly to Model 1, and also fK-independence of Sz (Fig. S3B).
Gradual increase of r as the KLK activation increases (towards the
top right corner of Fig. S3C) is also exhibited for Model 2,
similarly for Model 1.
Effects of degradation rates on model behaviours
In order to systematically investigate the effects of model parameters
on system behaviours, we identified sensitive parameters for
inflammation level [PAR2*] by performing global sensitivity analysis
using eFAST [32,33]. Both Models 1 and 2 exhibit high sensitivity to
degradation rates of PAR2*, PAR2, KLK5*, and KLK5 (dP ,dP,dK ,
and dK), half-saturation of KLK5 and PAR2 activation (CK and CP),
the feedback strength for KLK5 production (fK), and pH-dependent
Figure 5. Bifurcations for Model 1 with different parameters. Calculated for 20|20 pair of feedback strength 0ƒfKƒ1 and 0ƒfLƒ0:5. KLK
production rate is higher at the bottom right corner. (Top) Bifurcation patterns with colours corresponding to those in Fig. 4A. Stronger KLK
activation results in more severe symptoms of irreversible bistability. (Middle) Inflammation threshold Sz for bistability patterns; Sz~0 for
monostability patterns. (Bottom) Range of bistability r for reversible bistability; r~0 for other patterns. The inflammation is more persistent (r is
larger) with stronger KLK activation. A: Comparison for HC, AD-LEKTI, and AD-pH. AD conditions exhibit smaller Sz and more severe symptoms than
HC. B: Comparison for different degradation rates for KLK5 and KLK5* in HC with dK~1 (nominal), dK~0:5 and dK~0:2. Slower KLK5 degradation
(smaller dK) results in the stronger KLK activity and shows similar effects as in AD-pH condition leading to more irreversible bistability patterns and
lower threshold values. C: Comparison for different degradation rates for PAR2 and PAR2* in HC with dP~0:5 (nominal) and dP~0:3. Slower PAR2
degradation (smaller dP) results in the stronger inflammation and shows similar effects as in AD-LEKTI condition leading to more irreversible
bistability patterns and little changes in threshold values.
doi:10.1371/journal.pone.0019895.g005
Figure 6. Sensitivity indicator for Models 1 and 2 calculated by eFAST. Global sensitivity analysis of Models 1 and 2 with respect to the
steady state level of inflammation [PAR2*]. Baseline parameter values are given in Table 1. Parameters were perturbed over one order of magnitude
(N =2000 simulations for eFAST).
doi:10.1371/journal.pone.0019895.g006
Skin Barrier Homeostasis in Atopic Dermatitis
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19895activation rates for KLK5 and PAR2 (k and kP) (Fig. 6). Model 1 is
also sensitive to the feedback strength for LEKTI production (fL)a n d
LEKTI production rate tL. The sensitivity to PAR2 production rate
(mP) is also shown to be high; however, further study revealed mP only
affects the scaling of the inflammation level and not the bifurcations,
and thus mP-dependence was not investigated further. As the effects of
k,kP,tL were discussed earlier, we systematically changed the
remaining sensitive parameters together with the feedback strength
to determine their type of effects on bifurcations.
We first studied the effects of KLK5 degradation rates (dK~dK )b y
changing dK from 1 to 0.5 and 0.2, corresponding to the change of the
half-life from approximately 15 to 30 and 70 minutes, respectively
(Fig. 5B). Slower KLK5 degradation (smaller dK) results in the stronger
KLK5 activity, as KLK5 remains for a longer period of time, and thus
s h o w ss i m i l a re f f e c t sa si nA D - p Hc o ndition (Fig. 5A) leading to more
irreversible bistability patterns and lower thresholds. The system with
faster KLK5 degradation requires stronger (and thus faster) positive
feedback strength to compensate the fast degradation in order to
exhibit bistability. This result confirms the key role of the balance
between the KLK5 degradation rates and feedback strength in
determination of bifurcations. Similar effects were observed for half-
saturation of KLK5 and PAR2 activation (C~CK,CP) (Fig. S4), since
smaller C values also correspond to stronger activation.
We then investigated the effects of PAR2 degradation rates
(dP~dP ) by changing dP from 0.5 to 0.3, corresponding to the
change of the half-life from approximately 30 to 60 minutes
(Fig. 5C). Slower PAR2 degradation (smaller dP) results in the
stronger inflammation, as PAR2 stays for a longer period of time
to initiate inflammation. Thus, we observed similar effects as in
AD-LEKTI condition (Fig. 3A), in which KLK5* is less captured
by LEKTI and activates more PAR2, resulting in more
irreversible bistability patterns with little changes in thresholds.
Similar features were observed for Model 2: the effects of
decreasing dK (Fig. S5) and of decreasing C (Fig. S6) are similar to
those of AD conditions (Fig. S3). The pattern of irreversible
bistability becomes more relevant and the decrease of the
threshold values are observed. The effects of decreasing dP (Fig.
S7) is also similar to AD-LEKTI condition, as it changes the
bifurcation patterns but does not seem to significantly decrease the
threshold.
Characteristic features of AD and HC revealed by
microarray data
The model predictions should be compared against experimen-
tal data that had not been used for the model construction. For this
purpose, we analysed microarray data for AD and HC samples to
derive their respective characteristic features to be tested with our
models. While PAR2 activity, the key component in our model, is
not directly measurable by conventional experiments, the
downstream targets of PAR2 signalling are partially known to
include IL1, IL8 and other inflammatory genes, which can be
measured by microarray analysis. Here we propose a reasonable
indicator for the PAR2 activity by combining measurements of a
set of PAR2 downstream genes.
A microarray dataset of AD patients and HC was obtained from
the Gene Expression Omnibus (GEO) (accession number
GSE5667) [34]. Using this dataset, we calculated the score
(PAR2 score) which corresponds to the inflammation level in our
model by weighting the expression data of selected possible PAR2
downstream genes (ICAM1, IL8, TNFa, CSF2, IL1a, IL1b, and
CCL17 [21,35]). The weights were determined by the principal
component score that represents the difference between AD and
HC samples (see Methods). The original dataset for AD patients
includes that for both lesional (LAD) and non-lesional (NLAD)
skin area. LAD and NLAD were classified by the clinical features
of the regional skin. In definition, LAD samples are obtained from
eczematous skin regions with inflammation and NLAD samples
are the ones with apparently normal skin without inflammation.
The calculated PAR2 score was plotted against the expression
data of KLK5, SPINK5 (encoding LEKTI), and KLK7 in Fig. 7 for
LAD (red squares), NLAD (blue squares), and HC (black circles).
The dotted lines indicate the median of HC data that provides the
reference value. Due to the small number of data and the
individual variability, we are mostly concerned with whether the
data value is high or low relative to the reference. Most of LAD
and some of NLAD show high PAR2 score suggesting that
inflammatory processes occur at certain degrees in these skin
samples, whereas all of HC show low PAR2 scores, which reflect
the absence of inflammation and are considered to be a
background level in this analysis. This confirms that the PAR2
score calculated here is a reasonable indicator for the inflamma-
tion level.
Despite the small number of microarray samples, Fig. 7 exhibits
clear relationships between PAR2 score and each expression level
of KLK5, SPINK5, and KLK7. Data points with high PAR2 score
show low KLK5 expressions, although the point with the lowest
KLK5 expression level shows medium PAR2 score and thus no
clear negative correlation was observed. The negative correlation
between PAR2 score and SPINK5 expression exhibited in Fig. 7B
was consistently observed for different selections of possible PAR2
downstream genes (data not shown). A positive correlation
between PAR2 score and KLK7 expression is also observed,
Figure 7. Microarray data for AD and HC samples. PAR2 score was derived using the data [34] of seven PAR2 downstream genes (see
Methods). PAR2 score is plotted against expression data [34] of (A) KLK5, (B) SPINK5, and (C) KLK7 for lesional AD (red squares), non-lesional AD (blue
squares), and HC (black circles). The dotted lines indicate the median values of HC samples.
doi:10.1371/journal.pone.0019895.g007
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the skin desquamation process and activated by KLK5* while
unable to activate PAR2. The dynamics of KLK7 thus cannot be
captured in our model for KLK5 (Fig. 1C). The plots of PAR2
score and KLK7 expression is shown here for a comparison with
that of KLK5. Low expression of SPINK5 in AD (Fig. 7B) is
consistent with the data [14] showing lower LEKTI concentration
in AD. Some NLAD samples even showed low SPINK5 expression
despite the low PAR2 score, which suggests that the low
expressions of SPINK5 are not dependent on the inflammation
states of the skin.
The expressions of KLK5 were low in AD samples, especially in
those with high PAR2 score (Fig. 7A). It is not intuitively coherent
to the previous data [13] that KLK5 protein concentration is
higher in AD patients compared to HC. However, we note that
the data is on the production level of KLK5 and not the
concentration of KLK5 protein, and that KLK5 mRNA (associated
with the production rate) is suppressed while KLK5 protein level is
high in the later phase of a time course experiment [36]. The
positive correlation of KLK7 expression level with PAR2 score
(Fig. 7C) suggests that a different regulatory mechanisms is
operating in KLK7. The qualitative difference of KLK5 and KLK7
expression data suggests that the PAR2 activation and the
feedback via PAR2* is possibly an essential mechanism of
KLK5 activation regulation.
Model prediction captures characteristic features of AD
revealed by microarray data
The data showing the relationship between the expression levels
of KLK5 and SPINK5 and the calculated PAR2 score (Figs. 7A and
7B) were then compared with corresponding simulation results for
Models 1 and 2. In Fig. 8, the y-axis is the inflammation level
([PAR2*]) and the x-axis is KLK5 production level (FK) or LEKTI
production level (FL) calculated with S as a bifurcation parameter.
As before, the solid and dotted lines correspond to the stable and
unstable steady states, and the lines with different colours
correspond to different conditions: HC (black), AD-LEKTI (blue),
AD-pH (red) and AD-LEKTI/pH (green). AD-LEKTI/pH
condition denotes the case with limited LEKTI production rate
at pH 6.5, which is considered to reflect that of AD patients.
PAR2 score and expression data were roughly scaled to facilitate
the qualitative comparison of the data and the model results,
revealing the qualitative characteristics of the data is coherently
captured in the model results.
The observation of low KLK5 expression level for LAD with
high PAR2 score (Fig. 7A) were indeed remarkably reproduced by
the model behaviours (Fig. 8). In both models, the inflammation
level remains elevated even if the KLK5 production level
decreases for AD-pH and AD-LEKTI/pH conditions, in the
similar way as the inflammation level remains elevated despite a
decrease in external stimulus level (Fig. 3). The qualitative
characteristics of KLK5 expression level could thus be captured
by characteristic bistable behaviours exhibited by our models.
The negative correlation between PAR2 score and SPINK5
expression (Fig. 7B) was also clearly reproduced by the model
(Fig. 8). The production level of LEKTI (encoded by SPINK5) for
Model 1 (Fig. 8A) predicts that the high inflammation level is
achieved with low LEKTI production level for AD-LEKTI and
AD-LEKTI/pH conditions. Similarly, under negative feedback
(Model 2), low LEKTI production level occurs under AD-LEKTI
and AD-LEKTI/pH conditions when the inflammation level is
high; however, LEKTI production level for AD-LEKTI/pH
conditions becomes as high as that for HC and AD-pH conditions
when there is no inflammation (Fig. 8B).
While both the microarray data (Fig. 7A) and the model
behaviours (Fig. 8) consistently showed low KLK5 production rate
in AD especially at inflammatory states, the coherency of the
model results with the previous data showing high KLK5
concentration for AD [13] was supported by our model results
on the total concentration of all KLK5-related proteins (KLK5,
KLK5*, and LEKTI-KLK5*), which ELISA [13] measures. Both
Model 1 and Model 2 (Fig. S8) predict that the total KLK5 level is
higher for higher inflammation states, which is consistent with the
data in [13].
Accordingly, both the positive and negative feedback mechanisms
(Model 1 and Model 2, respectively) could capture qualitative
characteristics shown in the data. The combination of information
revealed on KLK5 and LEKTI production and inflammation may
suggest the main causes of the AD patients, either high pH or poor
LEKTI production. Notably, Models 1 and 2 display obviously
different behaviours for LEKTI production level vs inflammation level
for all conditions. To distinguish between the two models, we require
additional data, specifically uncovering information (such as pH or
SPINK5 mutation) for each sample, as described in the next section.
Discussion
Feedback regulation of KLK5 activity
The model development and analysis thus far confirmed that
our hypothesised core model mechanisms captured the essence of
inflammation outbreak by a defective skin barrier. Bifurcation
Figure 8. Model results of inflammation level against produc-
tion level of KLK5 and LEKTI. A: Model 1 with fK~0:6 and fL~0:1,
B: Model 2 with fK~0:8 and fL~2. Lines with different colours
correspond to different conditions: HC (black), AD-LEKTI (blue), AD-pH
(red), and AD-LEKTI/pH (green). Microarray data in Fig. 7 is plotted for
comparison after scaling: PAR2 score (y) is scaled by y{^ y yH
1:4 , where ^ y yH is
the median of fyg for HC, to compare with the inflammation level;
KLK5 (x1)a n dSPINK5 expression (x2)d a t aa r es c a l e db y
13(x1{^ x x1H)z13 and 1:8(x2{^ x x2H)z2:8 for comparison with Model
1, and 9(x1{^ x x1H)z8 and 1:2(x2{^ x x2H)z1:4 for comparison with
Model 2, where ^ x xiH is the median of fxig for HC. Data with positive
values are only shown here.
doi:10.1371/journal.pone.0019895.g008
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exhibited AD characteristics: the more susceptibility to external
stimulus, the stronger persistence of the inflammation, and the
prevalence of more severe symptoms described by irreversible
bistability for AD patients than for HC (Fig. 3B). While scattered
experimental evidence indirectly suggested the presence of
feedback mechanisms, there have been no previous attempts to
develop mathematical models for KLK5 activation system related
to skin barrier dysfunction. The coherency of our model results
with the experimental data (Fig. 8), together with the qualitative
difference we revealed in KLK5 and KLK7 expression data (Fig. 7),
confirmed the feedback mechanisms via PAR2 activation to
KLK5 and LEKTI production to be a key component in the
model. Based on this theoretical result, the actual existence of the
feedback from PAR2 to KLK5 and LEKTI should be experi-
mentally verified by future experiments, such as those proposed in
the next subsection.
Our model assumed the feedback from PAR2* to KLK5 to be
positive, reflecting the increase of KLK5 level at the occurrence of
the inflammation. The positive feedback from PAR2* to LEKTI
(Model 1) allowed the system to finely determine the appropriate
level of KLK activation by taking balance between two positive
feedbacks for KLK and LEKTI; when inflammation occurs, both
KLK5 and its inhibitor (LEKTI) are produced more to retain a
homeostatic level of KLK5 activity. Another model considered
assumed the negative feedback from PAR2* to LEKTI (Model 2).
It resulted in acceleration of KLK5 activity and inflammation as
KLK5 is produced more and its inhibitor (LEKTI) is produced less
when inflammation occurs. Intuitively, the presence of such
inherent positive acceleration is surprising: however, strong
acceleration provides an explanation for strong and persistent
inflammation in AD patients. The obvious difference of the results
by Models 1 and 2 with regard to the negative correlation between
PAR2 score and LEKTI production (Fig. 8) may prove useful to
distinguish the two models as more data become available.
Coupled feedback loops, either dual-positive or combination of
positive and negative loops are ubiquitously found in cellular
systems [37,38]. The combination of different kinematics, in
addition to the positiveness and negativeness, of interconnected
feedback loops have been found to play an important role to
decide the system behaviour. For example, the combination of fast
and slow (‘‘dual-time’’) positive feedback loops [37] and that of fast
positive and slow negative feedback loops [38] make the system to
be rapidly inducible and resistant to noise. The feedback strength
in our model represent the rate of feedback kinetics: stronger
feedback corresponds to faster feedback kinetics. Accordingly, it is
intriguing to experimentally assess the feedback kinetics, as
described below, to further our understanding of the regulatory
mechanisms.
Suggested experimental design for assessment of
feedback kinetics
The feedback terms FK and FL in our models are functions of
both [PAR2*] and S. The feedback mechanisms involving PAR2*
can be meaningfully assessed only through analysing the skin
samples from AD patients, as (1) PAR2* is incorporated as a
molecule that senses the inflammatory milieu in the skin barrier,
and (2) inflammation does not occur without immunocytes. The
other feedback through S, the basal activity of PAR2 correspond-
ing to the external stimulus in our model, can be suitably analysed
using organotypic culture of epidermis.
In the first system with clinical skin samples from AD patients,
immunohistochemistry of skin biopsies from AD patients and HC
using monoclonal antibodies (see below) against PAR2*, total
PAR2, KLK5, and LEKTI would measure per cell concentrations
of these proteins and provide information to deduce the feedback
strength. Presumptive time course data of inflammation might be
available by gathering the data of different skin lesions from an
individual if they are described by dermatological terms such as
erythema and plaque (roughly indicating early and chronic
inflammation, respectively). The spacial information of protein
concentration correlated with pathological features of the local
area in the skin (e.g. spongiosis indicating a degree of
inflammation) will be indispensable for future development of
partial differential equation models. As a direct relationship with
our current analysis, one can obtain a correlation between per cell
protein concentrations and the bulk analysis of mRNA (Figs. 7 and
8) if each skin biopsy sample is analysed by both the
immunohistochemistry and microarray.
The second system, organotypic culture of epidermis, is an
experimentally feasible system for obtaining time course samples of
basal PAR2 activation (S), KLK5 production rate and concen-
trations of KLK5 proteins without the influence of other cells
including immunocytes. Basal PAR2 level (S) can be experimen-
tally changed by mechanical stress and chemical stimulation. Time
course samples of the organotypic culture would be analysed by
real-time PCR of KLK5, LEKTI and PAR2 and by antibody-
staining of anti-KLK5, anti-PAR2*, and total PAR2* for protein
concentrations.
The two experimental systems described above require anti-
total PAR2 and anti-active and/or phosphorylated PAR2
antibodies. It is important to generate monoclonal antibodies
specific to the cleaved and/or phosphorylated form(s) of PAR2
protein [39] that can be used in both immunohistochemistry and
Western blotting.
Balance between degradation rates and feedback
strength
Depending on the system parameters, our model exhibited four
distinct behaviours in terms of bifurcation (Fig. 4A), among which
reversible and irreversible bistability patterns were biologically
plausible. We carried out the detailed study of parameter-
dependencies of bifurcation to see their effects on bifurcation
patterns, the inflammation threshold, and the range of bistability
(Fig. 5). Our analysis revealed that balance among different
parameters, especially that between KLK5 and PAR2 degradation
rates and feedback strength was important to determine the
bifurcations. Faster KLK5 and PAR2 degradation had to be
compensated by faster (stronger) positive feedback to KLK5 for
the system to exhibit biologically plausible bistability patterns.
Slow degradations of KLK5 and PAR2 had the similar effects as
AD-pH and AD-LEKTI conditions, respectively.
As a next step, it is critical to experimentally measure these key
parameters, the degradation rates of KLK5 and PAR2. PAR2
protein is either membrane bound or in the cytoplasm and its
degradation rate can be measured by the conventional degradation
assay with protein synthesis inhibitor, cycloheximide. However, the
degradation rate of KLK5 should be assessed in the extracellular
space,especially inthe skinbarrier,whichwe modelledinthis study.
As it is still obscure which mechanisms degrade KLK5 in this space,
the construction of in vitro degradation assay for KLK5 is difficult
and impractical. Thus, the degradation rate is ideally measured
using organotypic culture of epidermis, which is a culture system
that allows full differentiation of keratinocytes with the layer
structure as if likeepidermisand has both the granular and cornified
layer and therefore the skin barrier [40]. Time course analysis by
immunohistochemistry with an appropriate data analysis of
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extracellular KLK5 in the granular and cornified layers.
Microarray analysis of clinical samples
The model predictions were compared with the microarray data
to confirm the feasibility of our proposed models. We used the
microarray data for AD and HC samples to compare with the
model results for the following two reasons. First, although KLK5
and LEKTI protein levels in the corneal layer can be measured,
they may be different from the production rates by keratinocytes in
the granular layer, which we modelled in this study. Thus, mRNA
levels of these two genes may be one of the most reasonable and
appropriate approximates of the production rates of these proteins.
In fact, the protein expression levels of KLKs are increased when
mRNA of the corresponding KLKs is increased, and mRNA and
protein levels show significant correlations especially in the early
phase of various kinds of stimulation [36]. Second, the same
microarray analysis data allowed us to calculate PAR2 score, a
novel indicator for PAR2 signalling. The PAR2 score, together
with the expression data, clearly revealed characteristic features of
AD and HC samples (Fig. 7), which were successfully reproduced
by the model prediction (Fig. 8).
Our analysis suggests that microarray data can be more
efficiently analysed if they are accompanied with detailed clinical
features, which is rarely the case in published or publicly available
data from microarray experiments. As we presented here, PAR2
score was calculated by the expression and annotation data
(whether AD or HC) and was a useful indicator for assessing the
activities of PAR2 and the degree of inflammatory reactions. If the
current dataset was coupled with other annotation or clinical data
such as skin pH and clinical features of eczema, some other scales
could be made to analyse the correlations between the expression
data and these clinical data (categorical data). For example,
eczema may be described in various dermatological terms
including erythema and plaque, which can be correlated with
various conditions in our model. However, none of the currently
available microarray dataset in dermatological research has full
description of the skin lesion as far as the authors know. This is
mainly because not many methods have been proposed for
analysing both annotation and experimental data and because
Minimum Information About a Microarray Experiment, a
standard guideline for microarray experiments, does not suffi-
ciently emphasize the importance of such annotation data.
Microarray datasets with detailed clinical data would be
undoubtedly informative for mathematical modelling studies.
Possible further model development
There are several possible directions for further model
development.
Firstly, our model focused on KLK5, the primary KLK for skin
desquamation to capture the essence; however, KLKs constitute a
family of 15 serine proteases (KLK1–KLK15) that activate each
other. The network of KLK activation has been recently identified
in vitro [41] and thus shall be included in the future model.
Actually, AD is a paradigm case in which KLKs mediate
pathogenesis, as KLKs have recently been recognised to play an
important role in controlling both normal and pathological
extracellular proteolysis and signalling [42]. Uncontrolled proteo-
lytic activities of KLKs are associated with disease states including
cancer, inflammation, and neurodegeneration, and they are
overexpressed in various malignancies; for example, KLK3
expression is currently used as a marker for prostate cancer.
Accordingly, our work has potential impacts on the research for
these diverse diseases beyond AD and skin diseases.
Secondly, this model considered KLK5, LEKTI, and PAR2 as
main proteins regulating the KLK5 activity and characterised AD
patientsbylimited LEKTI production and high pH.However, there
have been increasing number of studies showing that AD is
associated with filaggrin deficiency, diminished level of skin lipids
and increased epidermal proliferation and that the resulting
congenital skin barrier defect is considered as the first trigger of
the development of AD [43]. In this relation, there are two major
consequences of the defective skin barrier that can be considered as
AD characteristics. The first one is the persistent increase of
percutaneous antigen penetration that could be avoided by the
healthy skin barrier. Whereas our work focused on the persistent
inflammationdespitethedecreaseofinitialexternal stimulusasaAD
characteristic to be shown by our model, the stimulus level is actually
difficult to be decreased for AD skin due to the persistent increase of
antigen penetration. As a result, AD skin may suffer from much
stronger persistence in inflammation. The effects of increased
penetration of antigen, and of the resulting stronger stimulus, may
be interpreted in our model analysis by rescaling the external
stimulus level (abscissa) in the bifurcation diagrams or by increasing
the feedback strengths fKS and fLS from S to KLK5 and LEKTI,
respectively, for congenital defective skin barrier. Effects of these
feedback strength can be investigated further in a similar way as in
Fig. 5. While our proposed model focused on the inflammation level
directly triggered by the external stimulus to elucidate the essential
relationship between the external stimulus and inflammation, this
increased stimulus level in AD skin shall be incorporated by adding
extra feedback loops from PAR2* to S in the future model. The
second AD characteristic resulting from the defective skin barrier is
the systemic sensitisation, that is, a quicker and larger responses to
antigens. It has been observed that an defective skin barrier
produced by tape stripping gave rise to increased cell density of
dendritic cells (e.g., Langerhans cells) [44], which play an important
role in triggering a Th2 immune response and atopic inflammation.
The sensitisation may be represented by the increased activation
rates for KLK5 and PAR2 in our model, or investigated further by
developing a systemic disease model, not a local model at the skin
surface, that explicitly includes the immune cells and their
interactions with keratinocytes.
The models developed in this paper were kept deliberately simple
to capture the essence of the regulatory mechanisms for KLK5
activity. Since detailed information is still lacking, our model results
are a first step to uncovering the mechanisms. Based on our findings,
we invite experimentalists to perform the experiments, including
those suggested above, to advance further model refinement and
development. Ultimately this may provide a unified and quantitative
basis for understanding possible causes of the disease, leading to
diagnostic indices and pharmaceutical targets. Especially, persistent
increase of percutaneous antigen penetration and systemic sensitisa-
tion mentioned above are two main features that shall be considered
in the future models to entangle the complex interactions among
genetic and environmental factors, the skin barrier, and immune
deficiencies that lead to AD manifestations.
Concluding remarks
This paper investigated feedback regulatory mechanisms for
skin barrier homeostasis through combination of (1) model
development based on recent experimental findings, (2) applica-
tion of sensitivity analysis and bifurcation analysis, and (3) model
validation using microarray data. To fill the gap between the
model studies and experimental studies, we proposed a novel
indicator for inflammation level, which is the key component of
our model but is difficult to be measured by conventional
experimental methods, by applying PCA to microarray data and
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further development of the model. AD is such a complex disease
that has not been fully captured by any experimental systems, and
its fundamental understanding will be extensively enhanced by a
systems-level investigation of the KLK5 activation mechanism
using model analysis like the one proposed here. This work is, to
the best of the authors’ knowledge, the first study for modelling
KLK5 activation system that is responsible for skin barrier
homeostasis, providing a framework to coherently understand the
current experimental knowledge on AD.
Methods
Model description
Our model (Fig. 1C) is described as
d½LEKTI{KLK5  
dt
~ ka½KLK5  ½LEKTI  { kd½LEKTI { KLK5   {
dLK½LEKTI{KLK5  ,
d½LEKTI 
dt
~{ka½KLK5  ½LEKTI zkd½LEKTI{KLK5  {
dL½LEKTI ztLFL,
d½KLK5  
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k
½KLK5  ½KLK5 
½KLK5  zCK
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½KLK5  ½KLK5 
½KLK5  zCK
{dK½KLK5 zFK,
d½PAR2 
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{dP½PAR2 zmP,
d½PAR2
  
dt
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½KLK5  ½PAR2 
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  ,
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  ,
FL~
mLzfLSSzfL½PAR2
  ,( M o d e l 1 )
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  zCL
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8
<
:
where ½X  indicates the concentration of X and S represents the
external stimulus level, i.e. basal activation level of PAR2 when there is
no inflammation (Fig. 2). KLK5 and PAR2 activations are described
by Michaelis-Menten type equations as they are bounded by the
availability of KLK5 and PAR2, respectively. The input functions FK
and FL correspond to production processes of KLK5 and LEKTI
proteins, respectively. We consider two models, Model 1 and Model 2,
which have positive and negative feedback from PAR2* to LEKTI,
respectively. We non-dimensionalised the ODE model des-
cribed above using the values ka~9:91|103 sec{1 M{1 and
kd~8:04|10{4 sec{1 obtained for pH 4.5 [12] in order to
minimise the effects of parameter uncertainties due to the lack of
knowledge in system parameters. All the other parameters are defined
relative to these numbers.
Parameter estimation
The system parameters in the model are summarised in Table 1
with their nominal values used for the simulation and sources for
each parameter estimate. Although estimates for some parameters
are not available and there is no way at present to extract these
numbers experimentally due to the difficulty in experiments, it is
still possible to derive meaningful conclusion by numerical
simulation and analysis of the model without them; especially
our model analysis aimed to capture qualitative, and not
quantitative, difference of HC and AD patients. Indeed, the lack
of parameter estimates motivates several specific experiments to
measure them, as proposed in the Discussion.
We investigated about 1000-fold range for each parameter to
identify the parameter range to exhibit bifurcation of our interest,
carried out global sensitivity analysis to identify sensitive
parameters, and studied the effects of changes in these sensitive
parameters on system behaviours. The activation rates (k,kP) and
half-saturation (CK,CP) for activation of KLK5 and PAR2 were
assumed to be same, as both KLK5 and PAR2 are activated by
KLK5* and there is no quantitative information available for their
difference. The degradation rates were assumed to be same for
active and inactive forms of KLK5 (dK,dK ,dLK) and PAR2
(dP,dP ) due to the lack of knowledge. Protease (KLK5)
degradation rate (dK) was considered to be larger compared to
those for LEKTI (dL) and PAR2 (dP). Basal production rate for
KLK5 (mL) was assumed to be 0 as it only shifts the KLK5
production rate and does not affect the dynamics (data not shown).
Rate of LEKTI production by stimulus for Model 2 (fLS) was
assumed to be 0 as the qualitative features discussed in this paper
were not affected by this parameter (data not shown).
Model analysis
We solved d½X =dt~0 to determine the steady state concen-
trations for each model species in terms of the parameters. Since
only one analytically tractable steady state was present, corre-
sponding to the zero ½PAR2   (non-inflammatory) state, the steady
state solutions were numerically calculated for the specific model
and its proposed conditions at fixed parameter values. The
number of steady states varied from one to three depending on the
parameter values.
In order to determine which parameters were responsible for
the number of fixed points and its corresponding stability, global
sensitivity analysis of Models 1 and 2 were performed using
eFAST. Parameters were perturbed over one order of magnitude
(N~2000 simulations). The calculated sensitivity indices motivat-
ed our selection of bifurcation parameters and numerical
bifurcation analysis was conducted.
To further investigate the behaviour of the stability of the system
while multiple parameters were varied, we constructed the
characteristic polynomial of the Jacobian evaluated at each steady
state (J ) and determined the stability of each steady state using the
Routh-Hurwitz criterion, a preferred method for nonlinear ODE
systems, which uses the coefficients of J  and hence bypasses
solving the roots of each polynomial [45,46]. We performed this
analysis for both Models using the nominal parameter values
(Table 1) unless otherwise stated while also varying three
parameters: stimulus level (S), feedback strength from PAR2* to
KLK5 (fK) and that to LEKTI (fL), to explore the behaviours of
inflammation level, ½PAR2  . Specifically, this stability analysis
enabled us to classify the monostable, bistable and irreversible
bistable ½PAR2   behaviours, ranges of bistability and threshold
value Sz governing the switch from a low to high ½PAR2   state.
Derivation of PAR2 score
PAR2 activity, the key component in our model, is not directly
measurable, since we cannot employ the common methods for
measuring signalling activities, such as phosphorylation of
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influx, due to the fact that the downstream signals of PAR2 include
MAPK and Ca2z release, both of which are not specific to PAR2.
However, the downstream targets of PAR2 signalling are partially
known and include IL1, IL8 and other inflammatory genes, which
we can measure by microarray analysis.
Microarray analysis has a unique feature that it measures ten of
thousands of genes at the same time and now widely used in
experimental medicine, while it is difficult to obtain many samples
because of the high costs. A reasonable indicator for the target
signal may be obtained by combining measurements of a set of the
related genes, although there has not been any established
methods to determine the appropriate weights for the measure-
ment of each gene transcript. Here we used principal component
analysis (PCA) to determine the reasonable weights based on our
recent findings (paper submitted by Ono et al.) that PCA
decomposes the variances between microarray samples and that
the method is further refined by employing a bootstrapping
technique. The PAR2 score derived in the way described below by
using PC scores as weights could successfully reflect the difference
between AD and HC groups.
Let E be a microarray expression data, where the j-th column
(j~1,...,N~22283) represents an expression level of the j-th
probe with the zero mean and the i-th row (i~1,...,17)
corresponds to the i-th individual (either AD patients or HC).
PCA applied to E provides the PC score S of the PC axis that
represents the difference between AD patients and HC. We used
a bootstrapping technique to get the PC score in a stable
manner as follows. At the k-th bootstrap repetition
(k~1,...,10000), n~5000 out of N probes on the affymetrix
microarray hgu133a are randomly resampled, and a new matrix
~ E Ek is obtained using both the resampled probes and the 13
probes corresponding to 7 selected PAR2 downstream genes
(ICAM1, IL8, TNFa, CSF2, IL1a, IL1b,a n dCCL17). PCA
applied to ~ E Ek provides the PC score Sk. Subsequently, we obtain
aP A R 2s c o r e ~ P Pk for the k-th bootstrap repetition by ~ P Pk~ ~ E E
p
k ~ S S
p
k,
where ~ E E
p
k and ~ S S
p
k are submatrices of ~ E Ek and ~ S Sk, respectively,
corresponding to the probes for the PAR2 downstream genes.
The distribution of the weights ~ S Sk (Fig. S9) indicated that
CCL17 (207900_at) has the largest contribution to the PAR2
score as a single probe, while IL-8 contributes almost
equivalently to the PAR2 score with its two probes
202859_x_at and 211506_s_at. The PAR2 score P is obtained
by taking the average of ~ P Pi.T h u s ,P represents the presumptive
effects of PAR2 downstream genes in terms of the disease
activity of AD in each individual.
Softwares
Oscill8 [47] were used for numerical bifurcation analyses.
Calculations of Routh-Hurwitz stability criterion were performed
using Maple 13 (Maplesoft, Waterloo, Ontario, Canada). Micro-
array data were normalised by mas5 of the affy package of
Bioconductor [48]. All figures were created using MATLAB
version R2009b (The MathWorks, Inc., Natick, MA, USA).
MATLAB add on toolboxes used include SBTOOLBOX2 [49]
for global sensitivity analysis and SBML export.
Supporting Information
Figure S1 Bifurcation diagram of Model 2 showing the
inflammation outbreak and its persistence. The solid and
dotted lines show the stable and unstable steady states,
respectively. The thickness of each bifurcation curve corresponds
to positive feedback strength (fK~0:4,0:6,0:8;fL~2). Stronger
positive feedback leads to more persistent inflammation, as is
shown by the larger range of the bistability.
(TIF)
Figure S2 Bifurcation behaviours of Model 2 for HC and
AD conditions. The behaviours are compared for HC (black),
AD-LEKTI (blue), and AD-pH (red) with fK~0:2 and fL~4. The
inflammation threshold is lower for AD conditions than that for
HC.
(TIF)
Figure S3 Bifurcations for Model 2 with different
feedback strength. Calculated for 20|20 pairs of feedback
strength in the range of 0ƒfKƒ1:0 and 0ƒfLƒ10 for HC, AD-
pH, and AD-LEKTI. A: Bifurcation patterns with colours
corresponding to those in Fig. 4A. B: Inflammation threshold
Sz. C: Range of bistability r for reversible bistability.
(TIF)
Figure S4 Bifurcations for Model 1 with different half-
saturation C for PAR2 and KLK5 activation. Calculated for
20|20 pair of feedback strength 0ƒfKƒ1 and 0ƒfLƒ0:5 for
C~50 (nominal), C~25 and C~15. A: Bifurcation patterns with
colours corresponding to those in Fig. 4A. B: Inflammation
threshold Sz for bistability patterns; Sz~0 for monostability
patterns. C: Range of bistability r for reversible bistability; r~0 for
other patterns.
(TIF)
Figure S5 Bifurcations for Model 2 with different
degradation rates for KLK5 and KLK5*. Calculated for
20|20 pairs of feedback strength in the range of 0ƒfKƒ1:0 and
0ƒfLƒ10 for dK~1 (nominal), dK~:5 and dK~:2.A :
Bifurcation patterns with colours corresponding to those in
Fig. 4A. B: Inflammation threshold Sz. C: Range of bistability
r for reversible bistability.
(TIF)
Figure S6 Bifurcations for Model 2 with different half-
saturation C for PAR2 and KLK5 activation. Calculated for
20|20 pairs of feedback strength in the range of 0ƒfKƒ1:0 and
0ƒfLƒ10 for C~50 (nominal), C~25 and C~15.A :
Bifurcation patterns with colours corresponding to those in
Fig. 4A. B: Inflammation threshold Sz for bistability patterns;
Sz~0 for monostability patterns. C: Range of bistability r for
reversible bistability; r~0 for other patterns.
(TIF)
Figure S7 Bifurcations for Model 2 with different
degradation rates for PAR2 and PAR2*. Calculated for
20|20 pair of feedback strength 0ƒfKƒ1 and 0ƒfLƒ0:5 for
dP~:5 (nominal) and dP~:3. A: Bifurcation patterns with colours
corresponding to those in Fig. 4A. B: Inflammation threshold Sz
for bistability patterns; Sz~0 for monostability patterns. C:
Range of bistability r for reversible bistability; r~0 for other
patterns.
(TIF)
Figure S8 Model results of total KLK level for HC and
AD conditions. Total KLK5 include KLK5, KLK5* and
LEKTI-KLK5*. The behaviours are compared for HC (black),
AD-LEKTI(blue), and AD-pH (red) Total KLK level is larger
when the external stimulus level is higher. A: Model 1 with
fK~0:8 and fL~0:4. B: Model 2 with fK~0:8 and fL~2.
(TIF)
Figure S9 Calculated weights of PAR2 downstream
genes for PAR2 score. Weights for 13 probes corresponding
Skin Barrier Homeostasis in Atopic Dermatitis
PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e19895to the seven PAR2 downstream genes (ICAM1, IL8, TNFa, CSF2,
IL1a, IL1b, and CCL17) were obtained by applying PCA to
microarray data with 10000 bootstrap repetition. Plots show the
median (red bar), 25–75th percentile (box plot), non-outlier range
(whiskers) and outliers (red cross) for each probe. ICAM(a):
202637_s_at ICAM1, ICAM(b): 202638_s_at ICAM1, ICAM(c):
215845_s_at ICAM1, IL8(a): 202859_x_at IL8, IL8(b):
211506_s_at IL8, TNFa: 207113_s_at TNFa, CSF(a): 210228_at
CSF2, CSF(b): 210229_s_at CSF2, IL1a(a): 208200_at IL1a,
IL1a(b): 210118_s_at IL1a, IL1b(a): 205067_at IL1b, IL1b(b):
39402_at IL1b, CCL17: 207900_at CCL17.
(TIF)
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